|
WO2014110277A1
|
|
Methods of treating developmental and personality disorders
|
|
WO2014052849A1
|
|
Combination treatments for bipolar disorders
|
|
CA2867851A1
|
|
Spirocyclic dihydro-thiazine and dihydro-oxazine bace inhibitors, and compositions and uses thereof
|
|
US2014194428A1
|
|
Combination treatments for bipolar disorders
|
|
SG195233A1
|
|
Scyllo-inositol for the treatment of behavioral and psychiatric disorders
|
|
WO2012173808A1
|
|
Scyllo-inositol for the treatment of behavioral and psychiatric disorders
|
|
CN103917525A
|
|
Inhibitors of LRRK2 kinase activity
|
|
WO2012074882A2
|
|
Phagocytic activity as a marker of synucleinopathic disease
|
|
WO2012051395A1
|
|
Methods of synthesis of scyllitol and related compounds
|
|
CA2814084A1
|
|
Inhibitors of polo-like kinase
|
|
AU2011211351A1
|
|
Methods and compositions for treating tumors and metastatic disease
|
|
WO2011137418A1
|
|
Selective integrin inhibitors
|
|
WO2011085136A2
|
|
Use of perlecan domain v in treating amyloidogenic disease
|
|
MX2012007273A
|
|
Pteridinones as inhibitors of polo - like kinase.
|
|
BRPI1015259A2
|
|
alpha-4 integrin pyridinone antagonists
|
|
EP2411388A2
|
|
Process for the production of fused, tricyclic sulfonamides
|
|
WO2010031051A1
|
|
Methods of treatment of hyperuricemia and associated disease states
|
|
KR20110055715A
|
|
N-sulfonamido polycyclic pyrazolyl compounds
|
|
WO2009086539A2
|
|
Treatment and prophylaxis of amyloidosis
|
|
EP2231185A1
|
|
Methods and compositions for treating liquid tumors
|
